Skip to content
Operation Infinite Justice – Lifestyle
Author:
Black Diamond Therapeutics, Inc
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 5, 2026
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
May 22, 2026
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
May 21, 2026
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
May 19, 2026
Black Diamond Group Limited Announces Renewal of Normal Course Issuer Bid
May 8, 2026
Black Diamond Group Limited Announces Approval of All Resolutions at 2026 Annual Meeting
May 7, 2026
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 7, 2026
Black Diamond Reports First Quarter Results and Declares Dividend
April 30, 2026
Black Diamond Group Announces Expansion Of Asset-Based Credit Facility
April 27, 2026
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
April 21, 2026
1
2
Next Page
→